CombiMatrix (CBMX) Skyrockets on Contract, Oncolytics (ONCY)

CombiMatrix Corporation (Nasdaq:CBMX)

Shares of CBMX soared on Thursday's trading session after the company reported that it has entered into a contractual agreement with America's Choice Provider Network(R) (ACPN(R)) for coverage of its diagnostic laboratory services.

The agreement with ACPN, a San Diego-based national healthcare savings provider network, provides access to CBMX 's suite of molecular diagnostic solutions and comprehensive clinical support—specializing in prenatal, miscarriage and pediatric healthcare—to more than 14 million members.

CBMX provides valuable molecular diagnostic solutions and comprehensive clinical support for the highest quality of care — specializing in miscarriage analysis, prenatal and pediatric healthcare. CBMX offers comprehensive testing services for the detection of genetic abnormalities at the DNA level, beyond what can be identified through traditional methodologies.

More about CombiMatrix Corporation (Nasdaq:CBMX) at www.combimatrix.com

**

Oncolytics Biotech Inc. (Nasdaq:ONCY)

ONCY reported positive top-line data for the endpoints in its double blinded, randomized clinical study examining REOLYSIN(R) in combination with carboplatin and paclitaxel in patients with second-line platinum-refractory, taxane-naïve head and neck cancers (REO 018).

Overall, the treatment combination was found to be safe and well tolerated by patients.

ONCY 's REOLYSIN is a proprietary variant of the reovirus, an acronym for Respiratory Enteric Orphan Virus, which is widely found in the environment. By adulthood, most people have been exposed to the reovirus. The reovirus is non-pathogenic, which means that infections are typically asymptomatic.

Cancers that are known collectively as head and neck cancers usually begin in the squamous cells that line the moist, mucosal surfaces inside the head and neck (for example, inside the mouth, the nose, and the throat). These squamous cell cancers are often referred to as squamous cell carcinomas of the head and neck. Head and neck cancers can also begin in the salivary glands, but salivary gland cancers are relatively uncommon. Salivary glands contain many different types of cells that can become cancerous, so there are many different types of salivary gland cancer.

Alcohol and tobacco use (including smokeless tobacco, sometimes called “chewing tobacco” or “snuff”) are the two most important risk factors for head and neck cancers, especially cancers of the oral cavity, oropharynx, hypopharynx, and larynx. At least 75% of head and neck cancers are caused by tobacco and alcohol use. People who use both tobacco and alcohol are at greater risk of developing these cancers than people who use either tobacco or alcohol alone. Tobacco and alcohol use are not risk factors for salivary gland cancers.

Head and neck cancers account for approximately 3% of all cancers in the United States. These cancers are nearly twice as common among men as they are among women. Head and neck cancers are also diagnosed more often among people over age 50 than they are among younger people. (Source: National Cancer Institute)

To learn more about head and neck cancers, go to www.cancer.gov/cancertopics/factsheet/Sites-Types/head-and-neck

According to ONCY , the trial results demonstrate that REOLYSIN can be safely added to this chemotherapeutic combination (carboplatin and paclitaxel ).

ONCY believes that the addition of REOLYSIN to other regimens will not increase the frequency or severity of adverse events caused by the chemotherapeutic agents with which it is combined.

ONCY is a biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics.

More about Oncolytics Biotech Inc. (Nasdaq:ONCY) at www.oncolyticsbiotech.com .

**

Crown Equity Holdings Inc. (CRWE)

According to eMarketer, online retail sales will grow from $225.5 billion in 2012, to $434.2 billion in 2017.

U.S. companies and government agencies will purchase $559 billion via the web in 2013, Forrester Research Inc. predicted in its first estimate of the b2b e-commerce market released last year.

Looking to deliver value for its stockholders in both the near and long term, CRWE is refocusing its strategic plan to improve the potential future growth for the company, targeting the multi-billion dollar online video-sharing and online b2b markets, with its Division CRWETube ( www.crwetube.com ) and its iB2B Global project, respectively.

As a worldwide online multi-media publisher, CRWE ‘s advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness. CRWE launches, invests and manages select businesses, projects and real estate endeavors.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com .

**

Read Full Disclaimer at www.pennyomega.com/disclaimer